Aquacel Hypersensitivity Dressing in TJAs
| 対象疾患 | Contact Allergic Dermatitis, Adverse Skin Reaction |
|---|---|
| 相 | 第4相 |
| スポンサー | Rush University Medical Center |
| ステータス | 完了 |
| 参加者数 | 457 名 |
| 介入（薬剤） | Aquacel dressing |
| 開始日 | 2023年6月18日 |
| 完了日 | 2024年11月1日 |
| 結果公開日 | 2026年8月4日 |
概要
The aim of this multi-surgeon, single institution study is to prospectively evaluate the incidence of allergic contact dermatitis (ACD) following application of AQUACEL Ag, a silver-containing hydrofiber dressing, in total hip and knee arthroplasty patients. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
Number of Participants With Contact Allergic Dermatitis or Adverse Skin Reaction at 2 Weeks Post Surgery
| Arthroplasty-naïve Aquacel Group | 5 Participants |
|---|---|
| Prior Aquacel Group | 3 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen
- BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital